J&J
UK Launches Public-Private iDx-Lung Consortium to Improve Early Detection of Lung Cancers
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.
AnchorDx, Johnson & Johnson Collaborate on Early-Stage Lung Cancer Diagnosis Study
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
Thermo Fisher, Janssen Biotech to Develop CDx for Lung Cancer, Other Indications
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
Organizations including Quest, J&J, Medecision, and the ACCP have formed the Get the Medications Right (GTMRx) Institute to promote PGx testing.
Veracyte, Johnson & Johnson Innovation Collaborate on Lung Cancer Dx
Veracyte plans to launch a new version of its Percepta test and present data for a nasal swab lung cancer diagnostic this year.
Jul 10, 2018
Cue Health Closes $45M Series B Financing
Dec 12, 2016